Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.

BACKGROUND: Vaccination with a recombinant modified vaccinia Ankara expressing antigen 85A from Mycobacterium tuberculosis, MVA85A, induces high levels of cellular immune responses in UK volunteers. We assessed the safety and immunogenicity of this new vaccine in West African volunteers. METHODS AND...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Brookes, R, Hill, A, Owiafe, P, Ibanga, H, Jeffries, D, Donkor, SA, Fletcher, H, Hammond, A, Lienhardt, C, Adegbola, R, McShane, H
التنسيق:	Journal article
اللغة:	English
منشور في:	Public Library of Science 2008

مواد مشابهة

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
حسب: Roger H Brookes, وآخرون
منشور في: (2008-08-01)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
حسب: Roger H. Brookes, وآخرون
منشور في: (2011-01-01)

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.
حسب: Ibanga, H, وآخرون
منشور في: (2006)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
حسب: Owiafe, P, وآخرون
منشور في: (2012)

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.
حسب: Ota, M, وآخرون
منشور في: (2011)

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants
حسب: Ota, M, وآخرون
منشور في: (2011)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
حسب: Pathan, A, وآخرون
منشور في: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
حسب: Pathan, A, وآخرون
منشور في: (2012)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
حسب: Meyer, J, وآخرون
منشور في: (2013)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
حسب: Mcshane, H, وآخرون
منشور في: (2005)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
حسب: Whelan, K, وآخرون
منشور في: (2009)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
حسب: Meyer, J, وآخرون
منشور في: (2013)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
حسب: Rowland, R, وآخرون
منشور في: (2012)

The effect of tuberculin skin test and BCG vaccination on the expansion of PPD-specific IFN-gamma producing cells ex vivo.
حسب: Ota, M, وآخرون
منشور في: (2007)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
حسب: Harris, S, وآخرون
منشور في: (2011)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
منشور في: (2011-01-01)

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
حسب: White, A, وآخرون
منشور في: (2013)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
حسب: Minassian, A, وآخرون
منشور في: (2011)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
حسب: Hawkridge, T, وآخرون
منشور في: (2008)

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection
حسب: Betts, G, وآخرون
منشور في: (2012)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
حسب: Kathryn T. Whelan, وآخرون
منشور في: (2011-01-01)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
حسب: Sander, C, وآخرون
منشور في: (2009)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
حسب: Rowland, R, وآخرون
منشور في: (2013)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
حسب: Tameris, M, وآخرون
منشور في: (2014)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
حسب: Thomas, Z, وآخرون
منشور في: (2014)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
حسب: Minhinnick, A, وآخرون
منشور في: (2016)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
حسب: Odutola, A, وآخرون
منشور في: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
حسب: Odutola, A, وآخرون
منشور في: (2012)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
حسب: Fletcher, H, وآخرون
منشور في: (2008)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
حسب: Wajja, A, وآخرون
منشور في: (2017)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
حسب: Griffiths, K, وآخرون
منشور في: (2011)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel mycobacterium tuberculosis vaccine MVA85A
حسب: Griffiths, K, وآخرون
منشور في: (2011)

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.
حسب: Gareth Betts, وآخرون
منشور في: (2012-01-01)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
حسب: Harris, S, وآخرون
منشور في: (2013)

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults
حسب: Riste, M, وآخرون
منشور في: (2021)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
حسب: Tameris, M, وآخرون
منشور في: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
حسب: Satti, I, وآخرون
منشور في: (2014)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults
حسب: Wilkie, M, وآخرون
منشور في: (2019)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
حسب: Dieye, T, وآخرون
منشور في: (2013)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
حسب: Mcshane, H
منشور في: (2008)